AKAP8

Across TCGA pan-cancer cohorts, AKAP8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AKAP8 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AKAP8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKAP8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where AKAP8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.492	0.807	.002	43	view →
LUAD	DFS	Tertile	All	0.953	0.791	.004	12	view →
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	4	view →
CCRCC	DFS	Tertile	III,IV	0.830	0.198	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AKAP8–HNSC (DFS)

Open the HNSC breakdown →